

**PHARMAESSENTIA APPOINTS SULIN SHAH AS U.S. GENERAL COUNSEL,
HEAD OF COMPLIANCE**

Shah's robust industry experience will guide U.S. infrastructure growth and capability building

October 5, 2021, Burlington, MA – [PharmaEssentia Corporation](#) (TPEX: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Sulin Shah as U.S. General Counsel and Head of Compliance.

“Sulin is a recognized legal strategist and partner in the biopharmaceutical community and brings critical knowledge and guidance to help strongly position our team for operations in the coming years,” said Meredith Manning, General Manager of the U.S. subsidiary. “We are confident his robust industry experience will be a tremendous asset to our team and contribute to our success.”

Prior to joining PharmaEssentia, Mr. Shah served as U.S. General Counsel at Orphazyme where he supported extensive U.S. organizational and infrastructure development. Prior to Orphazyme, Shah was Lead Counsel in U.S. Hematology for Takeda, following the acquisition of Shire. Earlier in his career, he served in private legal practice and management consulting roles in Chicago. Shah earned his bachelor's degree in business administration from the University of Illinois and his J.D. from Northwestern University.

“It's inspiring to join the PharmaEssentia leadership team at such an important time in the company's journey, as we prepare to actively engage the U.S. MPN community,” said Mr. Shah. “Leveraging all of my past learnings, I look forward to helping this expert team grow and to providing productive guardrails to enable us to excel as an emerging biopharmaceutical leader.”

About PharmaEssentia

PharmaEssentia Corporation (TPEX: 6446), based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product already approved in Europe and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today the company is expanding its global presence with operations in the U.S., Japan, China and Korea, along with a world-class biologics production facility in Taichung. For more information, visit our [website](#) or find us on [LinkedIn](#) and [Twitter](#).

Media Contact:

Kellie Hotz, kellie_hotz@pharmaessentia.com

###